Compare PRM & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRM | LGND |
|---|---|---|
| Founded | 2018 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.9B |
| IPO Year | N/A | 1992 |
| Metric | PRM | LGND |
|---|---|---|
| Price | $26.79 | $197.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $28.00 | ★ $243.50 |
| AVG Volume (30 Days) | ★ 747.9K | 229.4K |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.76 |
| EPS | 0.52 | ★ 2.49 |
| Revenue | ★ $636,343,000.00 | $251,233,000.00 |
| Revenue This Year | $15.59 | $47.71 |
| Revenue Next Year | $18.64 | $9.77 |
| P/E Ratio | ★ $52.63 | $79.59 |
| Revenue Growth | 19.12 | ★ 64.83 |
| 52 Week Low | $8.76 | $93.58 |
| 52 Week High | $29.88 | $212.49 |
| Indicator | PRM | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 40.82 | 49.89 |
| Support Level | $27.87 | $188.13 |
| Resistance Level | $29.48 | $207.06 |
| Average True Range (ATR) | 1.09 | 8.91 |
| MACD | -0.21 | 0.03 |
| Stochastic Oscillator | 1.03 | 60.63 |
Perimeter Solutions Inc is a solutions provider for the Fire Safety and Specialty Products industries. The Company's products and operations are managed and reported in two operating segments. Its Fire Safety segment provides fire retardants and firefighting foams, as well as specialized equipment and services typically offered in conjunction with the Company's retardant and foam products. The Specialty Products segment includes operations that develop, produce and market products for non-fire safety markets. Specialty Products segment is Phosphorus Pentasulfide (P2S5) based lubricant additives. P2S5 is also used in pesticide and mining chemicals applications, and emerging electric battery technologies.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.